GRC 1087
Latest Information Update: 13 Feb 2008
At a glance
- Originator Glenmark Pharmaceuticals Ltd
- Class Obesity therapies
- Mechanism of Action Beta 3 adrenergic receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Diabetes mellitus; Obesity
Most Recent Events
- 11 Oct 2005 No development reported - Preclinical for Diabetes mellitus in India (unspecified route)
- 11 Oct 2005 No development reported - Preclinical for Obesity in India (unspecified route)
- 26 Aug 2003 This compound is still in active development